INNOTEST® PHOSPHO-TAU (181P) (96T)

Looking for additional resources?

Create your free e-services account and get access.
  • Find & download CoA, SDS and CE declarations of conformity
  • Unlimited acces to our free e-learning videos
  • See all event dates where our products are presented

Single-analyte assays using Elisa technology

 
Clinical background

Alzheimer’s disease (AD) is the most common form of dementia and is histologically characterized by the accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles throughout the brain. The major constituents of amyloid plaques are the β-amyloid peptides consisting of 40 and 42 amino acids, which are derived from the amyloid precursor protein. Neurofibrillary tangles are made up of paired helical filaments consisting of hyperphosphorylated tau protein (phospho-tau). Tau protein, present in the brain in 6 different isoforms, is an intracellular protein that is released upon neuronal death.

Art. # 80062 (RUO - 96 Tests) - Please contact your local Fujirebio representative for the availability of this product in your country.

RUO - for research use only. Not for use in diagnostic procedures.

 
Intended use

The INNOTEST® assay described here is a solid-phase enzyme immunoassay for the quantitative determination of phospho-tau(181P) in human cerebrospinal fluid (CSF). This assay is for research use only and not for use in diagnostic procedures.

 
Assay principle

[[{"attributes":{},"fields":{}}]]
 

Advantages of our assays

  • Simple colorimetric immunoassays that are easily automated on microplate-processor
  • Supported by many peer-reviewed scientific publications
  • Less than 300 μL of CSF necessary for determination of complete biomarker profile
  • Assay range consistent with biological range of values

 

A license regarding amyloid beta antibodies contained in this product under patents US 570349 and EP 0683234 has been obtained from Takeda Pharmaceutical Company Limited. Furthermore, a license for the use of amyloid beta monoclonal antibodies contained in this product under patents US 5,593,846A, US 5,766,846A, US 5,837,672A, US 6,284,221B1, US 6,610,493B1, US 5,441,870A, US 5,721,130A, US 5,605,811A and US 6,114,133A has been obtained from Eli Lilly and Company.

 

Additional resources:

These resources are either available in free access or for users holding a Premium eServices account:

CLOSE

You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Looking for additional resources?

Create your free eServices account and get access to all our extra documentation (certificates, data sheets, ...), event dates where our products are presented, FAQs, ...

  • Find & download CoA, SDS and CE declarations of conformity
  • Unlimited access to our free eLearning videos
  • See all event dates where our products are presented

Already have an account? Log in here

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.

Looking for additional resources?

Create your free e-services account and get access.
  • Find & download CoA, SDS and CE declarations of conformity
  • Unlimited acces to our free e-learning videos
  • See all event dates where our products are presented

Quick access